For example, in atopic dermatitis, combining a JAK inhibitor with dupilumab (an IL‐4/IL‐13 inhibitor) may enhance disease control while reducing the dosage requirements of each agent, thereby minimizing adverse effects [77, 78]. This evidence concerns the gene IL13 and atopic eczema.